Tyrosine

TAE Life Sciences Awarded Patent for Borylated Amino Acid Compositions for Boron Neutron Capture Therapy

Retrieved on: 
Tuesday, March 12, 2024
Neutron, Radiation, Patent, Tyrosine, Research, BTS, Cancer, Ome, BNCT, Pharmaceutical industry

IRVINE, Calif., March 12, 2024 /PRNewswire/ -- TAE Life Sciences, a leading innovator in cancer treatment technologies, today announced that the United States Patent and Trademark Office (USPTO) has granted the company's U.S. Patent No. US 11,884,688 B2, for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT). This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant milestone in the field of radiation therapy.

Key Points: 
  • US 11,884,688 B2 , for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT).
  • This new patent underscores TAE Life Sciences' commitment to advancing biologically targeted radiation therapy and marks a significant milestone in the field of radiation therapy.
  • "This patent represents a significant milestone for TAE Life Sciences, validating the innovative work of our research and development teams.
  • With this patent, TAE Life Sciences solidifies its position as a leader in radiation therapy innovation, poised to transform the landscape of cancer treatment.

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

Retrieved on: 
Friday, February 2, 2024
Partnership, Conjunctivitis, Medicine, Inflammation, Vitamin, Thrombocytopenia, Immune system, Tyrosine, Patient, Light, Nosebleed, Intellectual disability, Itch, Ageing, Diet, Keratitis, Skin, Pharmacy, Tongue, Rash, DSM-IV codes, Allergy, Blood, Leukopenia, Photophobia, Mouth ulcer, Phenylalanine, Erythroderma, Tell, Insurance, Face, Breast milk, Plasma, Nursing

DEER PARK, Ill., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Please see important safety information below. Tyrosinemia type 1 is an ultra-rare condition that is estimated to impact fewer than 500 patients in the United States.

Key Points: 
  • We believe that our existing commercial infrastructure and strong patient support services should help us capture a meaningful percentage of the estimated $50 million annual Nitisinone market,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
  • Nitisinone Capsules are available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions.
  • Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals.
  • To report a suspected adverse event related to Nitisinone, contact Eton Pharmaceuticals, Inc. at: 1-855-224-0233 or the US Food and Drug Administration at www.fda.gov/medwatch or call 1-800-FDA-1088.

NOW® Consumer Survey Unlocks Top Wellness and Health Priorities For 2024

Retrieved on: 
Tuesday, January 9, 2024
Nutrient, Intertek, Sleep, Research, National Organic Program, ISO 17025, Health, ALL, DNA, Pesticide, Caffeine, WADA, Memory, GMP, Good manufacturing practice, DNA profiling, Vitamin D, Food, Disease, Safety, NOW, Quality control, Dietary supplement, Liver, FDA, RDN, Tyrosine, Iodine, Microbiology

BLOOMINGDALE, Ill., Jan. 9, 2024 /PRNewswire/ -- It's no surprise that packed schedules and never-ending to-do lists weigh heavily on people's health, and the need for energy support to get through each day is a priority. In fact, a recent consumer survey commissioned by leading natural products manufacturer NOW® (Suzy.com, October 2023) revealed nearly half of respondents (48%) are looking for supplements to bolster their energy levels.  In addition to increased energy, respondents cited better sleep (35%), improved stress and mood support (30%) and cardiovascular/heart health support (26%) were top wellness priorities and opportunities to find quality supportive supplements.

Key Points: 
  • In addition to increased energy, respondents cited better sleep (35%), improved stress and mood support (30%) and cardiovascular/heart health support (26%) were top wellness priorities and opportunities to find quality supportive supplements.
  • Blatner recommends some NEW supplements from NOW to support consumers' stated wellness priorities.
  • *
    Improved Cardiovascular Function/Heart Health*: NOW® Heart Health Probiotic features Lactobacillus reuteri LRC™, the first heart health probiotic with scientific backing.
  • Do research to confirm any experts promoting the brand on social or other channels are legit and carry meaningful credentials within the health and wellness space.

ZOA Energy Launches Revolutionary Five-in-One Pre-Workout Supplement with Setria® Glutathione

Retrieved on: 
Tuesday, November 7, 2023
Research, Dwyane Wade, Sport, Food, Creatine, RD, Certification, Dwayne Johnson, MBA, Nitric oxide, Athlete, Interview, Β-Alanine, Trust, Rock, Disease, Tyrosine, Glutathione, NO, Alanine, Ginkgo, Safety, Citrulline, Electrolyte, Food and Drug Administration, Fatigue, Dietary supplement, ZOA, Amazon

NEW YORK, Nov. 7, 2023 /PRNewswire-PRWeb/ -- The newly launched ZOA+ Powder pre-workout supplement has discerning athletes running to hit the gym to maximize their workouts. ZOA+ includes premium ingredients like Setria®, a clinically studied and patented form of glutathione that helps to replenish the body's reserves*, in its five-in-one advanced formula with a powerful combination of Nitric Oxide (NO) alongside training support, natural caffeine, and electrolytes, while promoting focus for a peak performance workout.

Key Points: 
  • ZOA+ Powder is a natural addition to the growing list of products containing Kyowa Hakko's Setria® Glutathione.
  • Research suggests that Setria® Glutathione may support an increase in NO production when combined with L-Citrulline**, which is also contained in ZOA+.
  • Formulated by ZOA Energy Co-founder and Chief Innovation Officer, Dave Rienzi, ZOA+ Powder promises a superior fitness experience.
  • According to Rienzi, "This launch represents a remarkable stride for ZOA Energy, as we reshape the standards of excellence in the fitness industry and beyond."

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone

Retrieved on: 
Wednesday, October 4, 2023
Insurance, Cornea, Keratitis, US Foods, Tyrosine, Diet, Medicine, Tell, Face, Chapter 11, Title 11, United States Code, Erythroderma, Skin, Light, DSM-IV codes, Inflammation, Carglumic acid, Mouth ulcer, Rash, Phenylalanine, Intellectual disability, Eton, Plasma, Vitamin, Hair, Photophobia, Allergy, Patient, Leukopenia, Blood, Itch, Immune system, Cover My Eyes (Pain and Heaven), Ageing, Rare, FDA, Conjunctivitis, Nosebleed, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Thrombocytopenia, Tongue, Food, Breast milk, Pharmaceutical industry, Nursing, Dietary supplement, Medical imaging, Birth control, Nitisinone

DEER PARK, Ill., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced it has entered into an agreement to acquire an abbreviated new drug application for Nitisinone Capsules via Oakrum Pharma, LLC’s Chapter 11 bankruptcy proceeding. The transaction has been approved by the bankruptcy court and is expected to be effective on October 12, 2023. The acquired product was approved by the U.S. Food and Drug Administration (FDA) in May of 2023 for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. It is estimated that less than 500 patients in the United States suffer from this ultra-rare condition.

Key Points: 
  • Nitisinone is our fourth FDA-approved product, and further advances us toward our goal of having ten commercial rare disease products on the market by the end of 2025.
  • Eton expects to launch the product in the first quarter of 2024 and plans to offer its Eton Cares support program to all patients.
  • Nitisinone is a prescription medicine used to treat adults and children with a hereditary disease called tyrosinemia type 1 (HT-1).
  • To report a suspected adverse event related to Nitisinone, contact Eton Pharmaceuticals, Inc. at: 1-855-224-0233 or the US Food and Drug Administration at www.fda.gov/medwatch or call 1-800-FDA-1088.

Nitrase Therapeutics Announces Publication in the Journal of Biological Chemistry on the Role of Tyrosine Nitration in Cell Signaling and Cancer Biology

Retrieved on: 
Thursday, July 13, 2023
DAMP, Biochemistry, Database, Nitration, STAT1, Tyrosine, Phosphorylation, HER2, Hsps, CCL2, Bioorganic chemistry, Enzyme, Cancer, CXCL12, Sirtuin 2, LCK, Human, SHP2, DSM-IV codes, BCL2, Protein, Journal, B cell, HDAC2, Cell, Drug discovery, JAK2, Histone deacetylase 2, Sirtuin 6, Therapy, Janus kinase 2, SIRT6, SIRT2, Medical imaging

Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.

Key Points: 
  • Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.
  • The analysis revealed three major cellular networks that could be impacted by tyrosine nitration, resulting in altered protein function, localization, turnover, and protein-protein interactions.
  • Known sites of tyrosine nitration are also sites of phosphorylation, suggesting an extensive role for nitration in cell signaling, such that tyrosine nitration could profoundly interfere or alternatively complement tyrosine phosphorylation.
  • Tyrosine nitration is associated with different types of cancer by altering metabolic reprogramming and signaling.

Analog Pharma and Dipharma announce US FDA approval of abbreviated new drug application (ANDA) of 20 mg generic Nitisinone capsules (temperature stable)

Retrieved on: 
Wednesday, May 31, 2023
Cornea, Tyrosine, Analog, Hair loss, Pharmacy, Skin, Scar, Immunity, Nitisinone, Temperature, Liver transplantation, Cataract, Inflammation, Cell, Rash, Phenylalanine, Capsule, Patient, ANDA, Cover My Eyes (Pain and Heaven), Rare, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

PRINCETON, N.J. and CHIASSO, Switzerland, May 31, 2023 (GLOBE NEWSWIRE) -- Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug Administration.

Key Points: 
  • PRINCETON, N.J. and CHIASSO, Switzerland, May 31, 2023 (GLOBE NEWSWIRE) -- Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug Administration.
  • Nitisinone Capsules are a room temperature stable, AB-rated, generic equivalent of Swedish Orphan Biovitrum's Orfadin®, and are now available in 2, 5, 10 and 20 mg capsules.
  • Analog currently distributes the 2, 5, and 10 mg products through specialty pharmacies and now has available the 20 mg capsules for distribution.
  • Tanya Carro, Executive Vice President, Analog Pharma, commented, “With the approval of the 20 mg capsule, we now have a full complement of room temperature stable strengths for our generic Nitisinone.

Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, DUSP6, Abstract, AACR, Tyrosine, Therapy, MCD, ADCC, Tafasitamab, DLBCL, Multiple myeloma, Neoplasm, Immunomodulatory imide drug, Lenalidomide, Anti-CD19 immunotoxin, NHL, BRAF, MEK, IC50, BTK, SHP2, Messenger, SSE, HKEX, RAS, Patient, EGFR, RTK, NF1, III, Safety, Vaccine, Extrusion, Pharmaceutical industry

Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • In various multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) tumor models, ICP-490 demonstrates superior tumor killing activities, including overcoming lenalidomide resistance.
  • Cell viability assays reveal robust in vitro efficacies of ICP-490 against various MM and NHL(including DLBCL) cell lines with nanomolar IC50.
  • In contrast to its tumor killing effect, ICP-490 shows no cytotoxicity against normal human cells.

Battling Brain Fog? Opti Brain Can Help

Retrieved on: 
Monday, February 27, 2023
Allergy, Supplement, Fatigue, Trust, Tyrosine, Acetylcarnitine, Depression, Cognition, Brain, Diet, Dopamine, Citicoline, Menopause, Caffeine, Forgetting, Electronics, ADHD, Memory, COVID-19, Design

FORT LAUDERDALE, Fla., Feb. 27, 2023 /PRNewswire/ -- "Brain fog" is a term that is as common as it is vague. The colloquial concept of a fuzzy brain is used by millions around the world to describe a mental state in which a variety of symptoms contribute to sluggish cognition. This includes things like mild confusion, forgetfulness, and mental fatigue. Many conditions, such as ADHD, depression, allergies, and even menopause have been associated with brain fog, with the most infamous condition connected to a foggy state of mind being COVID-19.

Key Points: 
  • That's why Trust Supplement has created its popular nootropic blend Opti Brain .
  • Opti Brain improves mental cognition and clarity through a unique, transparent blend of ingredients optimized to boost brain power.
  • In the case of Opti Brain, this consists of a formula that includes:
    CDP-Choline and Alpha-GPC to help with neurotransmitter function.
  • With Opti Brain, customers know that they are getting a carefully formulated nootropic blend that can help them in the fight to reclaim their mental clarity.

Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor Cancers

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, Clinical trial, Investigational New Drug, Progressive disease, Courage, Phosphorylation, Metastasis, CAR, Growth, Patient, Tyrosine, MUC1, FDA, IND, Recurrence, Biotechnology, Partial-response maximum-likelihood, Memorial Sloan Kettering Cancer Center, Pharmaceutical industry, Vaccine, Phenylalanine

huMNC2-CAR22 targets MUC1* (muk 1 star), the growth factor receptor that drives the growth and metastasis of most solid tumor cancers.

Key Points: 
  • huMNC2-CAR22 targets MUC1* (muk 1 star), the growth factor receptor that drives the growth and metastasis of most solid tumor cancers.
  • Minerva’s first CAR T that targets MUC1*, huMNC2-CAR44, is already in a clinical trial for metastatic breast cancers.
  • However, for a durable response, we needed to overcome CAR T cell exhaustion, which is common to CAR T cell treatment of solid tumor cancers.
  • Unexpectedly, the 1XX mutations give the CAR T cells the added benefit of being able to recognize and kill the low antigen expressing cancer cells that lead to cancer recurrence.